title: Reply to H. Kantarjian et al.
authors.forename: Rüdiger
authors.initials: R
authors.lastname: Hehlmann
authors.forename: Joerg
authors.initials: J
authors.lastname: Hasford
authors.forename: Markus
authors.initials: M
authors.lastname: Pfirrmann
authors.forename: Michael
authors.initials: M
authors.lastname: Lauseker
authors.forename: Susanne
authors.initials: S
authors.lastname: Saußele
authors.forename: Andreas
authors.initials: A
authors.lastname: Hochhaus
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines